FDA Gets Green Light For Risk-Benefit Analysis From Ephedra Ruling
This article was originally published in The Tan Sheet
Executive Summary
An appellate court decision upholding FDA's ban of ephedra "will embolden FDA to challenge products that have a bad safety profile," according to Scott Bass, a food and drug law expert and partner at Sidley Austin (Washington, DC)
You may also be interested in...
Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups
Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups
Hatch, Cannon Oppose Risk-Benefit For Ephedra; Experts Discuss NPA Brief
"Nutritional supplements are not drugs and should not be regulated as such," Rep. Chris Cannon, R-Utah, said in response to inquiries about the possible review of the risk-benefit standard by the Supreme Court